Lam Wah Ee Hospital and AGTC Genomics Launch Multi-Cancer Early Detection (MCED) Testing

A New Era of Precision Cancer Screening Through Advanced Genomic Technology

Lam Wah Ee Hospital and AGTC Genomics are proud to announce the launch of Multi-Cancer Early Detection (MCED) testing, bringing one of the most advanced cancer screening technologies available today to patients in Malaysia.

Advancing the Fight Against Cancer Through Early Detection

Cancer remains one of the leading causes of death worldwide. Unfortunately, many cancers are only diagnosed after symptoms appear, often when the disease has already progressed to a more advanced stage. Early detection significantly improves treatment options, clinical outcomes, and survival rates.

To address this challenge, Lam Wah Ee Hospital has partnered with AGTC Genomics to offer MCED testing, an innovative blood-based screening test capable of detecting signals associated with multiple types of cancer from a single blood sample.

What is MCED?

Multi-Cancer Early Detection (MCED) is a next-generation cancer screening approach that analyzes circulating tumor DNA (ctDNA) released by cancer cells into the bloodstream. Using advanced genomic sequencing and bioinformatics technologies, MCED can identify cancer-associated genetic alterations that may indicate the presence of cancer, often before symptoms develop.

Unlike traditional screening methods that focus on a single cancer type, MCED enables simultaneous screening for multiple cancers through a simple blood draw.

Empowering Patients with Earlier Answers

The introduction of MCED provides patients with access to a powerful tool for proactive health management.

Potential benefits include:

• Screening for multiple cancer types through a single blood test

• Earlier detection before symptoms become apparent

• Increased opportunities for curative treatment

• Reduced diagnostic delays

• Greater peace of mind for individuals concerned about cancer risk

Supporting Clinicians with Advanced Diagnostic Insights

MCED is designed to complement, rather than replace, established cancer screening programs such as mammography, colonoscopy, Pap smears, and low-dose CT scans.

For healthcare professionals, MCED offers:

• An additional tool for cancer risk assessment

• Enhanced support for clinical decision-making

• Identification of patients who may benefit from further diagnostic evaluation

• Improved integration of precision medicine into routine clinical practice

Bringing World-Class Genomic Testing to Malaysia

The MCED test is performed by AGTC Genomics, a leading Malaysian precision medicine company with a CAP-accredited and ISO 15189-accredited clinical genomics laboratory. By conducting testing locally, patients and clinicians benefit from faster turnaround times, local expertise, and internationally recognized quality standards.

Professor Dr. Chee-Onn Leong, Founder and CEO of AGTC Genomics, commented:

"The future of cancer care lies in detecting disease earlier, when intervention is most effective. Through our collaboration with Lam Wah Ee Hospital, we are making cutting-edge genomic technologies more accessible to Malaysians and helping to transform healthcare from reactive treatment to proactive prevention."

A Shared Vision for Precision Healthcare

The collaboration between Lam Wah Ee Hospital and AGTC Genomics reflects a shared commitment to improving cancer outcomes through innovation, early detection, and precision medicine.

By combining clinical excellence with advanced genomic science, both organizations aim to empower patients and healthcare professionals with better tools to combat cancer and improve long-term health outcomes.

---

About Lam Wah Ee Hospital

Lam Wah Ee Hospital is one of Malaysia's leading charitable healthcare institutions, providing comprehensive and patient-centered medical services. The hospital continues to invest in innovative healthcare technologies to improve patient care and clinical outcomes.

About AGTC Genomics

AGTC Genomics is a leading Malaysian precision medicine and genomics company specializing in cancer genomics, liquid biopsy, comprehensive gene profiling, pharmacogenomics, hereditary disease testing, and multi-cancer early detection solutions. Through its CAP-accredited and ISO 15189-accredited laboratory, AGTC Genomics is committed to making precision medicine more accessible across Malaysia and Southeast Asia.